Cidara Therapeutics Inc.
14
1
4
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
14%
2 trials in Phase 3/4
50%
5 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine
Role: lead
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
Role: lead
A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388
Role: lead
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
Role: lead
Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
Role: lead
Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Role: lead
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Role: lead
A Single Ascending Dose Study of CD101 IV in Healthy Subjects
Role: lead
FungiScope - A Global Emerging Fungal Infection Registry
Role: collaborator
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Role: lead
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
Role: lead
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
Role: lead
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
Role: lead
An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects
Role: lead
All 14 trials loaded